Frazier Life Sciences VIII, L.P. 3
3 · Arcutis Biotherapeutics, Inc. · Filed Jan 30, 2020
Insider Transaction Report
Form 3
Frazier Life Sciences VIII, L.P.
10% Owner
Holdings
Series C Preferred Stock
Exercise: $0.00→ Common Stock (1,074,467 underlying)- 509,032
Common Stock
Series A Preferred Stock
Exercise: $0.00→ Common Stock (6,360,272 underlying)Series B Preferred Stock
Exercise: $0.00→ Common Stock (2,099,019 underlying)
Footnotes (2)
- [F1]Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock will automatically convert into 1 share of the issuer's Common Stock immediately upon the closing of the Issuer's initial public offering and has no expiration date.
- [F2]This report is filed jointly by Frazier Life Sciences VIII, L.P. ("FLS-VIII"), FHM Life Sciences VIII, L.P. ("FHM-VIII L.P.") and FHM Life Sciences VIII, L.L.C. ("FHM-VIII LLC"). Shares are held directly by FLS-VIII. FHM-VIII L.P. serves as the sole general partner of FLS-VIII and owns no shares directly. FHM-VIII LLC serves as the sole general partner of FHM VIII L.P. and owns no shares directly. Patrick J. Heron and James Topper are members of FHM-VIII LLC and share voting and dispositive power over the shares held by FLS-VIII; however, they disclaim beneficial ownership of the shares held by FLS-VIII except to the extent of their pecuniary interests therein.